Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Novel Anti-HER2 Monoclonal Antibody (4 minutes)
  • CME

Thomas Bachelot, MD, PhD, provides an update of key trial data on margetuximab in HER2-positive advanced breast cancer.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
person default
Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: September 11, 2020 Expiration: September 10, 2021

This program is divided into short segments that you can review from the activity landing page.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate recent practice-changing advances in the treatment of HER2-positive MBC
  • Identify new and emerging therapies for third line and beyond for HER2-positive MBC
  • Assess clinical trial results for novel HER2-directed and targeted therapies in this setting

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Adam M. Brufsky, MD, PhD

Professor of Medicine
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Adam M. Brufsky, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi, Puma, Roche, and Seattle Genetics.


Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Cristina Saura, MD, PhD, has disclosed she has received consulting fees or received travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche Ltd, Genomic Health, Merck, Novartis, Pfizer, Philips HealthWorks, Pierre Fabre, prIME Oncology, Puma, Seattle Genetics, Sanofi, and Synthon.
Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Leon Bérard
Lyon, France

Thomas Bachelot, MD, PhD, has disclosed that he has received consulting fees from Roche, Novartis, AstraZeneca, Pfizer, and Seattle Genetics.


Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has disclosed that his spouse or partner has ownership interest in AstraZeneca.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.


The goal of this activity is to improve the knowledge, competence, and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 11, 2020, through September 10, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Expert commentary from Cristina Saura, MD, PhD, with answers to frequently asked questions on managing HER2-positive metastatic breast cancer from CCO

person default Cristina Saura, MD, PhD Released: September 11, 2020

Commentary from Adam Brufsky, MD, on managing interstitial lung disease during trastuzumab deruxtecan treatment for HER2-positive metastatic breast cancer

Adam M. Brufsky, MD, PhD Released: September 10, 2020

From Clinical Care Options (CCO), watch video of expert discussions of testing for and targeting of HER2, HER3, and TROP2 in metastatic breast cancer

Mark D. Pegram, MD Michael F. Press, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.25 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 10, 2020 Expired: September 9, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?